Search Results
Aug 13, 2026, 08:00 ET Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
dedicated to delivering RNA therapeutics to the heart, today announced it has earned another $15 million milestone payment from Bristol Myers Squibb (NYSE: BMY) based on the successful delivery of a lead compound targeting an undisclosed cardiology indication under the Company's ongoing collaboration.
More news about: Atrium Therapeutics
May 12, 2026, 08:30 ET Wall Street's Cardiac Bet: Where Diagnostics Meet the Money
convergence: VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), BridgeBio Pharma (NASDAQ: BBIO), Bristol Myers Squibb (NYSE: BMY), Arrowhead Pharmaceuticals (NASDAQ: ARWR), and Amgen (NASDAQ: AMGN).
More news about: USA News Group
Apr 23, 2026, 08:00 ET Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
RNA therapeutics directly to the heart, announced today it has earned a $15 million development milestone payment from Bristol Myers Squibb (NYSE: BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication
More news about: Atrium Therapeutics
Feb 25, 2026, 08:55 ET NYSE Content Update: Two MSCI Indexes to Begin Trading on NYSE Arca Options
BellAmericares highlights the importance of increasing access to healthcareClosing BellBristol-Myers Squibb (NYSE: BMY) marks its annual meeting of top 100 global leadersFor market insights, IPO activity, and today's opening bell, download the NYSE TV App:
More news about: New York Stock Exchange
Feb 24, 2026, 09:35 ET Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
Company Limited (NYSE: TAK) and Compass Pathways plc (NASDAQ: CMPS), Pfizer Inc. (NYSE: PFE), Bristol Myers Squibb (NYSE: BMY).
More news about: Market News Updates
Feb 17, 2026, 17:31 ET Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight
projected to increase to around 173K by 2036.Leading juvenile idiopathic arthritis companies, such as Bristol-Myers Squibb (NYSE: BMY), UCB Biopharma (EBR: UCB), Novartis (SWX: NOVN), and others, are developing new juvenile idiopathic arthritis treatment drugs that can be available
More news about: DelveInsight Business Research, LLP
Feb 11, 2026, 17:31 ET EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
GNPX), Cullinan Oncology (NASDAQ: CGEM), Taiho Pharma, CSPC Pharmaceutical (HKG: 1093), AbbVie (NYSE: ABBV), Teligene, Bristol–Myers Squibb (NYSE: BMY), SystImmune, Black Diamond Therapeutics (NASDAQ: BDTX), Lantern Pharma (NASDAQ: LTRN), and others, are developing new EGFR-NSCLC treatment drugs
More news about: DelveInsight Business Research, LLP
Oct 17, 2025, 10:00 ET SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025
Oct. 17, 2025 /PRNewswire/ -- SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced the oral presentation of the first disclosure of the safety and efficacy data from the global phase I US-Lung-101 study (NCT05983432)
More news about: SystImmune, Inc.
Oct 13, 2025, 05:00 ET SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration
negative breast cancer ineligible for anti-PD(L)1 drugs. This milestone triggered a one-time payment of $250 million by Bristol Myers Squibb (NYSE: BMY), pursuant to the 2023 collaboration and exclusive license agreement between SystImmune and Bristol Myers Squibb. SystImmune is further eligible to receive
More news about: SystImmune, Inc.
Sep 18, 2025, 08:45 ET Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
AI, Inc. (NASDAQ: TEM), CRISPR Therapeutics (NASDAQ: CRSP), BioNTech SE (NASDAQ: BNTX), Bristol Myers Squibb Company (NYSE: BMY).
More news about: MarketNewsUpdates
Sep 17, 2025, 08:30 ET Advancing Cancer Research Brings New Hope for Patients Worldwide
Biotherapeutics Inc. (NASDAQ: IOVA), Merck & Co. Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN) and Bristol-Myers Squibb Co. (NYSE: BMY) — that are driving advances in these challenging therapeutic areas.
More news about: NetworkNewsWire